ScreenerHero
FYBFormycon AG
XETRA · DE · Healthcare · Biotechnology · formycon.com
19.30EUR+3.43%Mkt Cap: 370.75M $P/E: —

Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular …

Industry Peers

Biotechnology
Screen all
VX1
Vertex Pharmaceuticals Incorporated
$130.23BUSDP/E 32.1
VRTX
Vertex Pharmaceuticals Incorporated
$139.84BUSDP/E 32.2
REGN
Regeneron Pharmaceuticals, Inc.
$85.11BUSDP/E 20.4
MRNA
Moderna, Inc.
$69.62BUSD
ARGX
ARGENX SE
$60.19BUSDP/E 39.1
UCB
UCB SA
$45.16BUSDP/E 19.2
RVMD
Revolution Medicines, Inc.
$46.01BUSD
ONC
BeOne Medicines AG
$41.76BUSDP/E 66.2
RPRX
Royalty Pharma Plc Class A
$35.67BUSDP/E 33.2
ALNY
Alnylam Pharmaceuticals, Inc.
$32.46BUSDP/E 42.3
INSM
Insmed Incorporated
$28.53BUSD
22UA
BioNTech SE
$26.14BUSD
INCY
Incyte Corporation
$25.79BUSDP/E 16.2
GMAB
Genmab A/S
$20.83BUSDP/E 26.3
GMAB
Genmab A/S
$19.17BUSDP/E 26.2
ASND
Ascendis Pharma A/S
$17.03BUSDP/E 20.0
BBIO
BridgeBio Pharma, Inc.
$16.41BUSD
EXEL
Exelixis, Inc.
$13.48BUSDP/E 17.1
BMRN
BioMarin Pharmaceutical Inc.
$13.42BUSDP/E 187.4
CORT
Corcept Therapeutics Incorporated
$12.87BUSDP/E 264.5

Key Statistics

Company
Market Cap370.75M $
Enterprise Value311.42M $
Revenue (TTM)66.57M $
Gross Profit3.89M $
Net Income (TTM)-70.32M $
Revenue/Share3.767 USD
Last Price19.30 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees196
CountryDE
SectorHealthcare
IndustryBiotechnology
ISINDE000A1EWVY8
Valuation
P/E (Trailing)—
P/E (Forward)17.29
PEG—
EV/EBITDA30.46
EV/Revenue4.68
P/S—
P/B0.88
EPS (TTM)-1.42
EPS (Forward)1.11
52W Range
15.8031% of range26.95
52W High26.95 EUR
52W Low15.80 EUR
Profitability
Gross Margin8.04%
Oper. Margin-65.87%
EBITDA Margin15.36%
Profit Margin-145.46%
ROE-16.21%
ROA-8.75%
Growth
Revenue Growth242.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF11.72M $
CapEx (TTM)59.66M $
FCF Margin-49.34%
FCF Yield-8.86%
Net Debt-47.03M $
Net Debt/EBITDA-4.60
Balance Sheet
Debt/Equity0.02
Current Ratio2.04
Quick Ratio1.42
Book Value/Sh21.76 EUR
Cash/Share2.930 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)39.67 EUR
Upside (mean)+105.5%
Target Range30.00 EUR – 51.00 EUR
€30.00+105.5% to mean€51.00
# Analysts6
Ownership
Shares Out.17.67M
Float—
Insiders30.00%
Institutions31.26%
Technical
SMA 5019.01 (+1.5%)
SMA 20020.91 (-7.7%)
Beta0.72
S&P 52W Chg18.16%
Avg Vol (30d)3.00K
Avg Vol (10d)2.86K
Technical Indicators
RSI (14)48.0
MACD-0.0914
MACD Signal-0.0928
MACD Hist.+0.0014
BB Upper19.30 EUR
BB Middle18.81 EUR
BB Lower18.33 EUR
BB Width5.14%
ATR (14)0.5991 EUR
Vol Ratio (20d)0.91x